Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 90 | 2024 | 744 | 17.860 |
Why?
|
Tumor Microenvironment | 21 | 2023 | 418 | 3.900 |
Why?
|
Adipocytes | 7 | 2023 | 155 | 2.900 |
Why?
|
Neoplasm Metastasis | 22 | 2020 | 1056 | 2.760 |
Why?
|
Peritoneal Neoplasms | 14 | 2023 | 177 | 2.580 |
Why?
|
Neoplasms, Glandular and Epithelial | 12 | 2017 | 74 | 2.440 |
Why?
|
Omentum | 11 | 2023 | 71 | 2.170 |
Why?
|
Cancer Survivors | 3 | 2023 | 85 | 1.960 |
Why?
|
Proto-Oncogene Proteins c-met | 11 | 2015 | 199 | 1.820 |
Why?
|
Drug Resistance, Neoplasm | 14 | 2024 | 592 | 1.800 |
Why?
|
Cystadenocarcinoma, Serous | 7 | 2018 | 45 | 1.780 |
Why?
|
Female | 122 | 2024 | 44532 | 1.730 |
Why?
|
Cell Line, Tumor | 43 | 2023 | 2426 | 1.670 |
Why?
|
Gene Expression Regulation, Neoplastic | 23 | 2018 | 1197 | 1.610 |
Why?
|
Mice, Nude | 25 | 2020 | 790 | 1.570 |
Why?
|
Urokinase-Type Plasminogen Activator | 11 | 2015 | 47 | 1.560 |
Why?
|
Metformin | 7 | 2019 | 128 | 1.470 |
Why?
|
MicroRNAs | 11 | 2023 | 534 | 1.470 |
Why?
|
Fallopian Tubes | 5 | 2022 | 41 | 1.440 |
Why?
|
Humans | 155 | 2024 | 86643 | 1.410 |
Why?
|
Epithelial Cells | 13 | 2019 | 669 | 1.400 |
Why?
|
Antineoplastic Agents | 15 | 2020 | 2360 | 1.390 |
Why?
|
High-Throughput Screening Assays | 3 | 2019 | 55 | 1.330 |
Why?
|
Neoplasms | 15 | 2023 | 2898 | 1.310 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2013 | 427 | 1.300 |
Why?
|
Neoplasm Invasiveness | 20 | 2016 | 552 | 1.300 |
Why?
|
Fallopian Tube Neoplasms | 4 | 2021 | 35 | 1.290 |
Why?
|
Cancer-Associated Fibroblasts | 4 | 2023 | 36 | 1.260 |
Why?
|
Mice | 43 | 2023 | 11352 | 1.210 |
Why?
|
Fibronectins | 3 | 2014 | 93 | 1.160 |
Why?
|
Tumor Cells, Cultured | 22 | 2019 | 1041 | 1.150 |
Why?
|
Adnexal Diseases | 2 | 2023 | 17 | 1.140 |
Why?
|
Proteomics | 8 | 2022 | 212 | 1.130 |
Why?
|
Adipose Tissue | 4 | 2022 | 240 | 1.130 |
Why?
|
Cytoreduction Surgical Procedures | 3 | 2021 | 73 | 1.110 |
Why?
|
Xenograft Model Antitumor Assays | 13 | 2019 | 458 | 1.110 |
Why?
|
Animals | 63 | 2023 | 26582 | 1.080 |
Why?
|
5-Methylcytosine | 2 | 2024 | 112 | 1.060 |
Why?
|
Ovary | 5 | 2022 | 258 | 1.050 |
Why?
|
Cell Adhesion | 16 | 2017 | 420 | 1.030 |
Why?
|
Cell Proliferation | 18 | 2021 | 1578 | 1.020 |
Why?
|
Fibroblasts | 8 | 2015 | 729 | 1.020 |
Why?
|
Models, Biological | 5 | 2015 | 1749 | 0.980 |
Why?
|
Paclitaxel | 3 | 2016 | 460 | 0.960 |
Why?
|
Glycerol | 1 | 2023 | 32 | 0.930 |
Why?
|
Extracellular Matrix | 4 | 2015 | 232 | 0.880 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2024 | 71 | 0.880 |
Why?
|
Matrix Metalloproteinase 2 | 6 | 2009 | 44 | 0.860 |
Why?
|
Coculture Techniques | 9 | 2020 | 164 | 0.850 |
Why?
|
Tumor Burden | 6 | 2020 | 289 | 0.850 |
Why?
|
Disease Progression | 15 | 2019 | 1531 | 0.850 |
Why?
|
Glycogen | 2 | 2019 | 59 | 0.850 |
Why?
|
Antineoplastic Protocols | 1 | 2021 | 9 | 0.790 |
Why?
|
Cell Movement | 9 | 2019 | 758 | 0.780 |
Why?
|
Mental Health | 2 | 2021 | 162 | 0.770 |
Why?
|
Fatty Acid-Binding Proteins | 2 | 2020 | 26 | 0.760 |
Why?
|
Signal Transduction | 16 | 2019 | 3241 | 0.750 |
Why?
|
Carcinoma | 4 | 2015 | 436 | 0.740 |
Why?
|
Gene Expression Profiling | 5 | 2021 | 1384 | 0.730 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 73 | 0.720 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 10 | 2013 | 21 | 0.710 |
Why?
|
Receptors, Cell Surface | 8 | 2007 | 286 | 0.700 |
Why?
|
Epithelium | 8 | 2023 | 319 | 0.700 |
Why?
|
Matrix Metalloproteinase 9 | 8 | 2008 | 78 | 0.690 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 318 | 0.690 |
Why?
|
Liposomes | 2 | 2016 | 91 | 0.680 |
Why?
|
Pandemics | 3 | 2022 | 740 | 0.680 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 567 | 0.660 |
Why?
|
Genomics | 2 | 2021 | 720 | 0.650 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2021 | 1313 | 0.650 |
Why?
|
CD36 Antigens | 1 | 2018 | 13 | 0.640 |
Why?
|
Transgender Persons | 1 | 2020 | 95 | 0.640 |
Why?
|
Depression | 2 | 2021 | 473 | 0.640 |
Why?
|
Stress, Psychological | 1 | 2021 | 313 | 0.630 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2017 | 28 | 0.600 |
Why?
|
Endometrial Neoplasms | 5 | 2020 | 193 | 0.580 |
Why?
|
Integrin alpha5beta1 | 4 | 2011 | 13 | 0.580 |
Why?
|
Aged, 80 and over | 20 | 2021 | 6509 | 0.570 |
Why?
|
Blotting, Western | 9 | 2015 | 782 | 0.570 |
Why?
|
Promoter Regions, Genetic | 16 | 2015 | 937 | 0.540 |
Why?
|
Cadherins | 4 | 2009 | 151 | 0.540 |
Why?
|
Integrin alpha5 | 3 | 2013 | 6 | 0.530 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 143 | 0.530 |
Why?
|
Transcription Factor AP-1 | 9 | 2007 | 65 | 0.530 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 853 | 0.500 |
Why?
|
Aged | 29 | 2022 | 18415 | 0.490 |
Why?
|
Disease Models, Animal | 5 | 2013 | 2232 | 0.490 |
Why?
|
Antibodies, Monoclonal | 4 | 2013 | 1376 | 0.480 |
Why?
|
Carcinogenesis | 3 | 2021 | 195 | 0.470 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 4 | 1997 | 85 | 0.460 |
Why?
|
Middle Aged | 31 | 2021 | 25028 | 0.460 |
Why?
|
Hepatocyte Growth Factor | 6 | 2010 | 84 | 0.440 |
Why?
|
Stromal Cells | 4 | 2019 | 143 | 0.440 |
Why?
|
Mitogen-Activated Protein Kinases | 6 | 2001 | 222 | 0.440 |
Why?
|
Spheroids, Cellular | 2 | 2017 | 31 | 0.440 |
Why?
|
Apoptosis | 7 | 2016 | 1683 | 0.440 |
Why?
|
Hypoglycemic Agents | 4 | 2019 | 378 | 0.430 |
Why?
|
Immunohistochemistry | 15 | 2020 | 1753 | 0.430 |
Why?
|
Biomarkers, Tumor | 11 | 2020 | 1464 | 0.430 |
Why?
|
Anoikis | 2 | 2011 | 7 | 0.430 |
Why?
|
Prognosis | 15 | 2019 | 3679 | 0.430 |
Why?
|
Cell Culture Techniques | 5 | 2017 | 188 | 0.420 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.410 |
Why?
|
HIV Infections | 1 | 2020 | 772 | 0.400 |
Why?
|
Salpingectomy | 1 | 2011 | 3 | 0.400 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2011 | 7 | 0.390 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 81 | 0.390 |
Why?
|
Mutation | 8 | 2023 | 3968 | 0.390 |
Why?
|
Anilides | 1 | 2011 | 47 | 0.390 |
Why?
|
Cell Communication | 4 | 2018 | 194 | 0.390 |
Why?
|
Cell Survival | 5 | 2020 | 969 | 0.380 |
Why?
|
Proteome | 3 | 2022 | 124 | 0.380 |
Why?
|
Ovariectomy | 1 | 2011 | 81 | 0.380 |
Why?
|
Tissue Adhesions | 1 | 2011 | 50 | 0.380 |
Why?
|
Glucose | 4 | 2023 | 638 | 0.380 |
Why?
|
Hyaluronic Acid | 1 | 2011 | 49 | 0.380 |
Why?
|
Estradiol | 1 | 2011 | 252 | 0.380 |
Why?
|
Vitronectin | 2 | 2008 | 6 | 0.380 |
Why?
|
Quinolines | 1 | 2011 | 95 | 0.380 |
Why?
|
Glycolysis | 4 | 2019 | 129 | 0.380 |
Why?
|
Receptor, ErbB-2 | 3 | 2008 | 223 | 0.370 |
Why?
|
Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.360 |
Why?
|
Integrin alphaVbeta3 | 1 | 2009 | 17 | 0.360 |
Why?
|
Norethindrone | 1 | 2009 | 12 | 0.360 |
Why?
|
Ethinyl Estradiol | 1 | 2009 | 16 | 0.360 |
Why?
|
Indoles | 1 | 2011 | 318 | 0.360 |
Why?
|
Neuropeptides | 3 | 2004 | 112 | 0.360 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2021 | 72 | 0.350 |
Why?
|
Ligands | 3 | 2023 | 433 | 0.350 |
Why?
|
Neoplasm Proteins | 5 | 2020 | 532 | 0.350 |
Why?
|
Gene Expression Regulation, Enzymologic | 4 | 2001 | 214 | 0.350 |
Why?
|
Adult | 24 | 2021 | 25648 | 0.350 |
Why?
|
RNA, Messenger | 10 | 2018 | 1981 | 0.340 |
Why?
|
Up-Regulation | 6 | 2020 | 712 | 0.340 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2009 | 103 | 0.340 |
Why?
|
Peritoneum | 3 | 2018 | 57 | 0.340 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2007 | 302 | 0.330 |
Why?
|
rac GTP-Binding Proteins | 3 | 2004 | 25 | 0.330 |
Why?
|
Tissue Culture Techniques | 1 | 2009 | 79 | 0.330 |
Why?
|
Piperidines | 1 | 2010 | 181 | 0.320 |
Why?
|
Pyridines | 2 | 2010 | 310 | 0.320 |
Why?
|
RNA, Small Interfering | 6 | 2019 | 547 | 0.320 |
Why?
|
Integrin beta1 | 1 | 2007 | 33 | 0.320 |
Why?
|
Cells, Cultured | 7 | 2019 | 2818 | 0.320 |
Why?
|
Transfection | 7 | 2015 | 896 | 0.310 |
Why?
|
BRCA1 Protein | 2 | 2021 | 200 | 0.310 |
Why?
|
Carcinoma, Endometrioid | 4 | 2020 | 43 | 0.310 |
Why?
|
Thrombin | 1 | 2007 | 61 | 0.310 |
Why?
|
Neoplasm Staging | 8 | 2017 | 1939 | 0.310 |
Why?
|
Disease-Free Survival | 7 | 2017 | 1204 | 0.310 |
Why?
|
Homeodomain Proteins | 4 | 2014 | 536 | 0.300 |
Why?
|
Keratins | 4 | 2007 | 63 | 0.300 |
Why?
|
Neoplasm Grading | 6 | 2017 | 357 | 0.290 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2019 | 273 | 0.280 |
Why?
|
Antigens, Neoplasm | 2 | 2018 | 325 | 0.280 |
Why?
|
Genome, Human | 2 | 2015 | 756 | 0.270 |
Why?
|
Transcription Factors | 8 | 2009 | 1565 | 0.270 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 879 | 0.270 |
Why?
|
Down-Regulation | 6 | 2020 | 504 | 0.260 |
Why?
|
Collagenases | 5 | 2001 | 39 | 0.260 |
Why?
|
Inflammation | 1 | 2011 | 920 | 0.260 |
Why?
|
Receptors, Glucocorticoid | 2 | 2017 | 120 | 0.260 |
Why?
|
Survival Rate | 6 | 2017 | 1863 | 0.260 |
Why?
|
Mass Spectrometry | 3 | 2022 | 188 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2018 | 322 | 0.260 |
Why?
|
Pseudogenes | 1 | 2004 | 35 | 0.250 |
Why?
|
Extracellular Vesicles | 2 | 2023 | 42 | 0.250 |
Why?
|
Retrospective Studies | 8 | 2023 | 8489 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 860 | 0.250 |
Why?
|
Pyrazoles | 2 | 2020 | 153 | 0.250 |
Why?
|
Breast Neoplasms | 6 | 2008 | 2903 | 0.250 |
Why?
|
Lymphatic Metastasis | 3 | 2005 | 486 | 0.250 |
Why?
|
Sensitivity and Specificity | 4 | 2023 | 1991 | 0.250 |
Why?
|
Biomarkers | 3 | 2024 | 1718 | 0.240 |
Why?
|
Genital Neoplasms, Female | 2 | 2016 | 107 | 0.240 |
Why?
|
Cell Cycle | 3 | 2011 | 502 | 0.240 |
Why?
|
Laminin | 3 | 2001 | 85 | 0.240 |
Why?
|
Ultrasonography | 2 | 2023 | 695 | 0.240 |
Why?
|
Phosphoprotein Phosphatases | 3 | 2018 | 57 | 0.230 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 134 | 0.230 |
Why?
|
Phosphorylation | 6 | 2015 | 1106 | 0.230 |
Why?
|
Neovascularization, Pathologic | 2 | 2019 | 353 | 0.230 |
Why?
|
Receptor Cross-Talk | 1 | 2023 | 33 | 0.230 |
Why?
|
Circulating MicroRNA | 1 | 2023 | 12 | 0.230 |
Why?
|
Transcriptome | 3 | 2023 | 580 | 0.220 |
Why?
|
Phosphates | 1 | 2023 | 160 | 0.220 |
Why?
|
Mice, Inbred BALB C | 4 | 2018 | 1047 | 0.220 |
Why?
|
Obstetric Labor, Premature | 1 | 2023 | 58 | 0.220 |
Why?
|
Chromatography, Liquid | 2 | 2020 | 104 | 0.220 |
Why?
|
Molecular Sequence Data | 9 | 2013 | 3030 | 0.220 |
Why?
|
Tandem Mass Spectrometry | 2 | 2020 | 103 | 0.220 |
Why?
|
DNA Methylation | 4 | 2020 | 628 | 0.220 |
Why?
|
rac1 GTP-Binding Protein | 4 | 2009 | 48 | 0.210 |
Why?
|
Postmenopause | 1 | 2022 | 98 | 0.210 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 303 | 0.210 |
Why?
|
Anxiety | 2 | 2021 | 287 | 0.210 |
Why?
|
Gene Knockdown Techniques | 2 | 2020 | 236 | 0.210 |
Why?
|
Cell Growth Processes | 3 | 2015 | 83 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 1373 | 0.210 |
Why?
|
Gene Expression | 4 | 2016 | 1284 | 0.210 |
Why?
|
Lysophospholipids | 2 | 2019 | 63 | 0.210 |
Why?
|
Heterografts | 2 | 2020 | 98 | 0.210 |
Why?
|
Fatty Acids | 1 | 2022 | 130 | 0.210 |
Why?
|
Genes, ras | 3 | 1997 | 96 | 0.200 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 151 | 0.200 |
Why?
|
Leukocyte Elastase | 1 | 2021 | 8 | 0.200 |
Why?
|
Protein Binding | 6 | 2013 | 1456 | 0.200 |
Why?
|
Hydrolases | 2 | 2018 | 28 | 0.200 |
Why?
|
Platinum | 1 | 2021 | 63 | 0.200 |
Why?
|
Premature Birth | 1 | 2023 | 113 | 0.200 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 1621 | 0.200 |
Why?
|
Endopeptidases | 1 | 2001 | 116 | 0.200 |
Why?
|
Neutrophils | 2 | 2021 | 307 | 0.190 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 329 | 0.190 |
Why?
|
Plasminogen | 1 | 2001 | 41 | 0.190 |
Why?
|
Transcriptional Activation | 5 | 2002 | 280 | 0.190 |
Why?
|
Lipid Metabolism | 2 | 2020 | 196 | 0.190 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 1997 | 101 | 0.190 |
Why?
|
BRCA2 Protein | 1 | 2021 | 158 | 0.190 |
Why?
|
Melanoma | 2 | 2022 | 459 | 0.190 |
Why?
|
MutL Protein Homolog 1 | 1 | 2020 | 33 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-jun | 4 | 2007 | 33 | 0.190 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 1 | 2020 | 23 | 0.190 |
Why?
|
Protein Array Analysis | 1 | 2020 | 50 | 0.180 |
Why?
|
Regulatory Sequences, Nucleic Acid | 2 | 2001 | 148 | 0.180 |
Why?
|
Chromatin | 1 | 2022 | 380 | 0.180 |
Why?
|
ras Proteins | 1 | 2001 | 128 | 0.180 |
Why?
|
Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 22 | 0.180 |
Why?
|
Endometriosis | 2 | 2011 | 58 | 0.180 |
Why?
|
Biphenyl Compounds | 1 | 2020 | 68 | 0.180 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2019 | 56 | 0.180 |
Why?
|
beta Catenin | 2 | 2014 | 251 | 0.180 |
Why?
|
Metabolomics | 1 | 2020 | 68 | 0.180 |
Why?
|
Transplantation, Heterologous | 2 | 2012 | 363 | 0.180 |
Why?
|
Immunotherapy | 3 | 2020 | 629 | 0.180 |
Why?
|
Cohort Studies | 6 | 2023 | 2767 | 0.180 |
Why?
|
Nicotinamide N-Methyltransferase | 1 | 2019 | 6 | 0.180 |
Why?
|
Enzymes | 1 | 2019 | 47 | 0.170 |
Why?
|
Amino Acid Sequence | 5 | 2018 | 2062 | 0.170 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 68 | 0.170 |
Why?
|
Base Sequence | 9 | 2013 | 2330 | 0.170 |
Why?
|
Extracellular Traps | 1 | 2018 | 11 | 0.170 |
Why?
|
Carboplatin | 1 | 2020 | 286 | 0.170 |
Why?
|
Obesity | 2 | 2018 | 963 | 0.170 |
Why?
|
Cell Death | 3 | 2021 | 256 | 0.170 |
Why?
|
Matrix Metalloproteinase Inhibitors | 2 | 2009 | 14 | 0.170 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2019 | 51 | 0.170 |
Why?
|
Metabolic Networks and Pathways | 1 | 2019 | 79 | 0.170 |
Why?
|
Transcription, Genetic | 6 | 2008 | 1135 | 0.170 |
Why?
|
RNA | 1 | 2022 | 560 | 0.170 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 80 | 0.170 |
Why?
|
Primary Cell Culture | 2 | 2016 | 72 | 0.160 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 87 | 0.160 |
Why?
|
Bevacizumab | 1 | 2019 | 281 | 0.160 |
Why?
|
Ultraviolet Rays | 1 | 1999 | 193 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 1 | 2021 | 311 | 0.160 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 217 | 0.160 |
Why?
|
Cysteine Proteases | 1 | 2017 | 4 | 0.160 |
Why?
|
Enzyme Assays | 1 | 2017 | 16 | 0.160 |
Why?
|
Binding Sites | 8 | 2002 | 1098 | 0.160 |
Why?
|
Cells | 1 | 2017 | 32 | 0.160 |
Why?
|
Plasminogen Activators | 1 | 1997 | 11 | 0.150 |
Why?
|
Mice, Transgenic | 2 | 2011 | 1540 | 0.150 |
Why?
|
Microfilament Proteins | 1 | 2019 | 208 | 0.150 |
Why?
|
Mice, Knockout | 3 | 2019 | 1924 | 0.150 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2018 | 105 | 0.150 |
Why?
|
Receptors, Prolactin | 1 | 2017 | 10 | 0.150 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2019 | 185 | 0.150 |
Why?
|
Energy Metabolism | 1 | 2019 | 271 | 0.150 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2008 | 113 | 0.150 |
Why?
|
Neoplasms, Experimental | 1 | 2018 | 269 | 0.150 |
Why?
|
Leukocytes | 1 | 2018 | 202 | 0.150 |
Why?
|
Embryo Implantation | 2 | 2023 | 25 | 0.150 |
Why?
|
Endothelial Cells | 4 | 2019 | 428 | 0.150 |
Why?
|
MAP Kinase Signaling System | 3 | 2018 | 192 | 0.150 |
Why?
|
Hyaluronan Receptors | 1 | 2016 | 36 | 0.150 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2018 | 315 | 0.150 |
Why?
|
Patient-Centered Care | 1 | 2019 | 203 | 0.140 |
Why?
|
Genetic Testing | 1 | 2021 | 535 | 0.140 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2016 | 27 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.140 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1996 | 137 | 0.140 |
Why?
|
Phylogeny | 2 | 2016 | 1137 | 0.140 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2007 | 262 | 0.140 |
Why?
|
fas Receptor | 2 | 2021 | 75 | 0.140 |
Why?
|
Genomic Instability | 1 | 2016 | 79 | 0.140 |
Why?
|
Cell Cycle Checkpoints | 1 | 2016 | 63 | 0.140 |
Why?
|
Carbon | 1 | 2016 | 80 | 0.140 |
Why?
|
Peritoneal Cavity | 1 | 2015 | 21 | 0.140 |
Why?
|
Models, Statistical | 1 | 2019 | 574 | 0.140 |
Why?
|
Protease Inhibitors | 3 | 2021 | 72 | 0.140 |
Why?
|
Exosomes | 1 | 2016 | 50 | 0.140 |
Why?
|
Adenosine | 1 | 2018 | 225 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 372 | 0.140 |
Why?
|
Organ Culture Techniques | 1 | 2015 | 135 | 0.130 |
Why?
|
Software | 1 | 2019 | 654 | 0.130 |
Why?
|
Risk Factors | 3 | 2021 | 5417 | 0.130 |
Why?
|
Cantharidin | 1 | 2015 | 2 | 0.130 |
Why?
|
Escin | 1 | 2015 | 2 | 0.130 |
Why?
|
Prochlorperazine | 1 | 2015 | 2 | 0.130 |
Why?
|
Tomatine | 1 | 2015 | 2 | 0.130 |
Why?
|
Biguanides | 1 | 2015 | 7 | 0.130 |
Why?
|
Benzophenanthridines | 1 | 2015 | 23 | 0.130 |
Why?
|
Carrier Proteins | 1 | 2019 | 673 | 0.130 |
Why?
|
Inhibitory Concentration 50 | 1 | 2015 | 64 | 0.130 |
Why?
|
Uterine Neoplasms | 2 | 2010 | 227 | 0.130 |
Why?
|
Fibroblast Growth Factor 1 | 1 | 2014 | 5 | 0.130 |
Why?
|
Niclosamide | 1 | 2014 | 10 | 0.130 |
Why?
|
Isoquinolines | 1 | 2015 | 72 | 0.130 |
Why?
|
Survival Analysis | 4 | 2012 | 1538 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 74 | 0.120 |
Why?
|
Cell Cycle Proteins | 1 | 1997 | 388 | 0.120 |
Why?
|
Integrins | 1 | 2014 | 76 | 0.120 |
Why?
|
Cell Line | 6 | 2009 | 2468 | 0.120 |
Why?
|
Hyperglycemia | 1 | 2015 | 176 | 0.120 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2014 | 87 | 0.120 |
Why?
|
Macrophages, Peritoneal | 1 | 2014 | 21 | 0.120 |
Why?
|
Drug Synergism | 1 | 2014 | 303 | 0.120 |
Why?
|
Hyperlipidemias | 1 | 2014 | 95 | 0.120 |
Why?
|
Arsenates | 1 | 2013 | 2 | 0.120 |
Why?
|
Wnt Proteins | 1 | 2014 | 123 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-raf | 4 | 1997 | 47 | 0.120 |
Why?
|
Cross-Cultural Comparison | 1 | 1993 | 34 | 0.110 |
Why?
|
Young Adult | 3 | 2021 | 5976 | 0.110 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 128 | 0.110 |
Why?
|
Genes, Reporter | 3 | 2001 | 268 | 0.110 |
Why?
|
Animals, Genetically Modified | 1 | 2013 | 181 | 0.110 |
Why?
|
Mitochondria | 1 | 2016 | 535 | 0.110 |
Why?
|
Colonic Neoplasms | 1 | 1997 | 556 | 0.110 |
Why?
|
Neoplasm Transplantation | 2 | 2011 | 391 | 0.110 |
Why?
|
Carcinosarcoma | 1 | 2012 | 20 | 0.110 |
Why?
|
Oxidative Stress | 1 | 2015 | 447 | 0.100 |
Why?
|
Estrogens | 2 | 2009 | 200 | 0.100 |
Why?
|
Estrogen Antagonists | 1 | 2011 | 48 | 0.100 |
Why?
|
Gonadoblastoma | 1 | 2011 | 1 | 0.100 |
Why?
|
Dysgerminoma | 1 | 2011 | 7 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1995 | 683 | 0.100 |
Why?
|
Enzyme Induction | 3 | 2016 | 88 | 0.100 |
Why?
|
SOX9 Transcription Factor | 1 | 2011 | 23 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2012 | 150 | 0.100 |
Why?
|
Tamoxifen | 1 | 2012 | 168 | 0.100 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 1 | 2011 | 18 | 0.100 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 363 | 0.100 |
Why?
|
Drug Interactions | 1 | 2011 | 248 | 0.100 |
Why?
|
Ovarian Cysts | 1 | 2011 | 17 | 0.100 |
Why?
|
Taxoids | 1 | 2011 | 129 | 0.100 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2010 | 31 | 0.100 |
Why?
|
HMGA2 Protein | 2 | 2007 | 14 | 0.100 |
Why?
|
Sequence Deletion | 2 | 2009 | 205 | 0.100 |
Why?
|
Mast Cells | 1 | 2011 | 92 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 1169 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2010 | 74 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 378 | 0.090 |
Why?
|
Treatment Outcome | 5 | 2016 | 7993 | 0.090 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 166 | 0.090 |
Why?
|
Intestinal Obstruction | 1 | 2011 | 88 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 2011 | 105 | 0.090 |
Why?
|
Adolescent | 2 | 2021 | 8981 | 0.090 |
Why?
|
Mullerian Ducts | 1 | 2009 | 17 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2007 | 79 | 0.090 |
Why?
|
Pelvic Pain | 1 | 2011 | 80 | 0.090 |
Why?
|
Protein Isoforms | 2 | 2021 | 270 | 0.090 |
Why?
|
Gonadotropins | 1 | 2009 | 34 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 4 | 1997 | 645 | 0.090 |
Why?
|
Hysterectomy | 1 | 2011 | 146 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2010 | 153 | 0.090 |
Why?
|
Child | 1 | 2021 | 6927 | 0.090 |
Why?
|
Ascites | 2 | 2023 | 55 | 0.090 |
Why?
|
Ovarian Diseases | 1 | 2009 | 32 | 0.090 |
Why?
|
Chronic Disease | 1 | 1993 | 971 | 0.090 |
Why?
|
Integrases | 1 | 2009 | 59 | 0.090 |
Why?
|
Administration, Oral | 1 | 2011 | 684 | 0.090 |
Why?
|
Trophoblasts | 1 | 2009 | 33 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2011 | 246 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2011 | 589 | 0.090 |
Why?
|
rho GTP-Binding Proteins | 1 | 2009 | 54 | 0.090 |
Why?
|
Precision Medicine | 1 | 2013 | 395 | 0.080 |
Why?
|
Intestine, Small | 1 | 2011 | 303 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 154 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2007 | 938 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 2271 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2009 | 165 | 0.080 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2008 | 12 | 0.080 |
Why?
|
Cattle | 1 | 2009 | 376 | 0.080 |
Why?
|
Methylation | 2 | 2019 | 251 | 0.080 |
Why?
|
DNA-Binding Proteins | 4 | 2015 | 1208 | 0.080 |
Why?
|
Abdominal Cavity | 1 | 2008 | 18 | 0.080 |
Why?
|
Receptor, PAR-1 | 1 | 2007 | 2 | 0.080 |
Why?
|
Histones | 2 | 2021 | 311 | 0.080 |
Why?
|
Procollagen-Proline Dioxygenase | 1 | 2007 | 10 | 0.080 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2007 | 31 | 0.080 |
Why?
|
CA-125 Antigen | 1 | 2007 | 22 | 0.080 |
Why?
|
Liver | 2 | 2005 | 1230 | 0.080 |
Why?
|
Models, Animal | 1 | 2009 | 263 | 0.080 |
Why?
|
Vimentin | 1 | 2007 | 44 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1995 | 1076 | 0.080 |
Why?
|
Chloramphenicol O-Acetyltransferase | 3 | 1996 | 28 | 0.080 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2007 | 12 | 0.080 |
Why?
|
Sp1 Transcription Factor | 2 | 2005 | 19 | 0.080 |
Why?
|
Thyroid Neoplasms | 2 | 2005 | 408 | 0.080 |
Why?
|
Chicago | 1 | 2012 | 1379 | 0.070 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 11 | 0.070 |
Why?
|
Phenotype | 4 | 2019 | 2378 | 0.070 |
Why?
|
Time Factors | 5 | 2018 | 5210 | 0.070 |
Why?
|
Mice, SCID | 2 | 2018 | 252 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2007 | 158 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2008 | 170 | 0.070 |
Why?
|
DNA | 3 | 2004 | 1294 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 3362 | 0.070 |
Why?
|
Genes, jun | 2 | 1996 | 18 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2006 | 79 | 0.070 |
Why?
|
Antibodies | 1 | 2008 | 350 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2022 | 1019 | 0.070 |
Why?
|
Tissue Fixation | 2 | 2020 | 40 | 0.070 |
Why?
|
Paraffin Embedding | 2 | 2020 | 78 | 0.070 |
Why?
|
Mutagenesis | 2 | 2015 | 199 | 0.070 |
Why?
|
Fibrocystic Breast Disease | 1 | 2005 | 12 | 0.070 |
Why?
|
Breast | 1 | 2007 | 288 | 0.070 |
Why?
|
Gene Expression Regulation | 4 | 2002 | 1920 | 0.070 |
Why?
|
Brain Stem Neoplasms | 1 | 2005 | 17 | 0.060 |
Why?
|
Cell Division | 5 | 2012 | 696 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2007 | 322 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2008 | 403 | 0.060 |
Why?
|
Blotting, Southern | 1 | 2004 | 129 | 0.060 |
Why?
|
Hyperplasia | 1 | 2005 | 148 | 0.060 |
Why?
|
Gestational Trophoblastic Disease | 1 | 2004 | 2 | 0.060 |
Why?
|
Pregnancy | 4 | 2023 | 2894 | 0.060 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2004 | 173 | 0.060 |
Why?
|
Sarcoma | 1 | 2006 | 215 | 0.060 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2006 | 173 | 0.060 |
Why?
|
Tissue Array Analysis | 2 | 2017 | 124 | 0.060 |
Why?
|
Dactinomycin | 1 | 2004 | 36 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2015 | 689 | 0.060 |
Why?
|
Cell Membrane | 1 | 2007 | 666 | 0.060 |
Why?
|
Bone Marrow | 1 | 2006 | 435 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 407 | 0.060 |
Why?
|
Gelatinases | 2 | 2001 | 10 | 0.060 |
Why?
|
Receptors, Progesterone | 1 | 2005 | 167 | 0.060 |
Why?
|
Metalloendopeptidases | 2 | 2001 | 45 | 0.060 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2004 | 416 | 0.060 |
Why?
|
Hypoxia | 1 | 2009 | 641 | 0.060 |
Why?
|
Sequence Alignment | 1 | 2004 | 351 | 0.060 |
Why?
|
ErbB Receptors | 1 | 2007 | 485 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2004 | 114 | 0.060 |
Why?
|
Methotrexate | 1 | 2004 | 249 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2019 | 615 | 0.060 |
Why?
|
Cloning, Molecular | 1 | 2004 | 646 | 0.060 |
Why?
|
Ascitic Fluid | 1 | 2023 | 37 | 0.060 |
Why?
|
RNA Splicing | 1 | 2004 | 142 | 0.060 |
Why?
|
Blotting, Northern | 2 | 2001 | 256 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2006 | 275 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2005 | 217 | 0.060 |
Why?
|
Liquid Biopsy | 1 | 2023 | 33 | 0.060 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 384 | 0.060 |
Why?
|
Proteins | 3 | 2004 | 777 | 0.060 |
Why?
|
Liver Neoplasms | 2 | 2010 | 736 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 2438 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-fos | 2 | 2007 | 68 | 0.050 |
Why?
|
Laser Capture Microdissection | 1 | 2022 | 20 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2012 | 3640 | 0.050 |
Why?
|
Delivery, Obstetric | 1 | 2023 | 112 | 0.050 |
Why?
|
Prenatal Care | 1 | 2023 | 72 | 0.050 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2003 | 106 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2016 | 1961 | 0.050 |
Why?
|
Pilot Projects | 1 | 2005 | 839 | 0.050 |
Why?
|
Endothelium, Vascular | 2 | 2002 | 435 | 0.050 |
Why?
|
Gastrins | 1 | 2001 | 15 | 0.050 |
Why?
|
Enzyme Precursors | 1 | 2001 | 20 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2002 | 1014 | 0.050 |
Why?
|
Transcription Factor AP-2 | 3 | 2007 | 14 | 0.050 |
Why?
|
Morbidity | 1 | 2022 | 148 | 0.050 |
Why?
|
Eosinophil Cationic Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2021 | 5 | 0.050 |
Why?
|
Receptors, Vitronectin | 1 | 2001 | 5 | 0.050 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2001 | 36 | 0.050 |
Why?
|
Pancreatic Elastase | 1 | 2021 | 15 | 0.050 |
Why?
|
Nuclear Proteins | 3 | 2002 | 696 | 0.050 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2001 | 17 | 0.050 |
Why?
|
Homologous Recombination | 1 | 2021 | 51 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2005 | 533 | 0.050 |
Why?
|
Allosteric Regulation | 1 | 2021 | 68 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 3092 | 0.050 |
Why?
|
Chemokine CCL2 | 1 | 2001 | 47 | 0.050 |
Why?
|
Reperfusion | 1 | 2001 | 31 | 0.050 |
Why?
|
Luciferases | 1 | 2001 | 118 | 0.050 |
Why?
|
Proteolysis | 1 | 2021 | 100 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 268 | 0.050 |
Why?
|
Protein Domains | 1 | 2021 | 128 | 0.050 |
Why?
|
Cryopreservation | 1 | 2001 | 69 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2001 | 113 | 0.050 |
Why?
|
MAP Kinase Kinase 1 | 2 | 1997 | 36 | 0.050 |
Why?
|
Enzyme Inhibitors | 3 | 2001 | 639 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2011 | 2207 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2001 | 238 | 0.050 |
Why?
|
Blood Platelets | 1 | 2001 | 149 | 0.050 |
Why?
|
Succinate-CoA Ligases | 1 | 2019 | 3 | 0.050 |
Why?
|
Prolyl Hydroxylases | 1 | 2019 | 3 | 0.050 |
Why?
|
Membrane Transport Proteins | 1 | 2001 | 166 | 0.050 |
Why?
|
Flavonoids | 2 | 1997 | 85 | 0.050 |
Why?
|
Trans-Activators | 1 | 2002 | 429 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 42 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2019 | 134 | 0.040 |
Why?
|
Swine | 1 | 2021 | 555 | 0.040 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 70 | 0.040 |
Why?
|
S-Adenosylhomocysteine | 1 | 2019 | 9 | 0.040 |
Why?
|
S-Adenosylmethionine | 1 | 2019 | 15 | 0.040 |
Why?
|
NF-kappa B | 1 | 2002 | 444 | 0.040 |
Why?
|
Antigens, CD | 1 | 2001 | 458 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2001 | 428 | 0.040 |
Why?
|
Placenta | 1 | 2000 | 175 | 0.040 |
Why?
|
Niacinamide | 1 | 2019 | 116 | 0.040 |
Why?
|
Heparin | 1 | 2019 | 175 | 0.040 |
Why?
|
Mechanistic Target of Rapamycin Complex 2 | 1 | 2018 | 11 | 0.040 |
Why?
|
Protein Precursors | 1 | 1999 | 143 | 0.040 |
Why?
|
Societies, Scientific | 1 | 2019 | 44 | 0.040 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 61 | 0.040 |
Why?
|
Sphingosine | 1 | 2019 | 71 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2001 | 999 | 0.040 |
Why?
|
HeLa Cells | 2 | 2011 | 498 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 187 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2019 | 116 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2022 | 1565 | 0.040 |
Why?
|
Transforming Growth Factor beta | 2 | 2016 | 301 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2018 | 213 | 0.040 |
Why?
|
Genetic Engineering | 1 | 2018 | 114 | 0.040 |
Why?
|
Tretinoin | 1 | 1998 | 126 | 0.040 |
Why?
|
Tissue Scaffolds | 1 | 2018 | 106 | 0.040 |
Why?
|
Dual Specificity Phosphatase 1 | 1 | 1997 | 17 | 0.040 |
Why?
|
Pre-Eclampsia | 1 | 2000 | 246 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 165 | 0.040 |
Why?
|
Vanadates | 1 | 1997 | 29 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 559 | 0.040 |
Why?
|
Protein Phosphatase 1 | 1 | 1997 | 34 | 0.040 |
Why?
|
Placental Lactogen | 1 | 2017 | 12 | 0.040 |
Why?
|
Oligonucleotides | 1 | 2017 | 92 | 0.040 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1997 | 46 | 0.040 |
Why?
|
Methyltransferases | 1 | 2018 | 182 | 0.040 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 1999 | 378 | 0.040 |
Why?
|
Prolactin | 1 | 2017 | 88 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 123 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 376 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2023 | 2379 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2016 | 28 | 0.040 |
Why?
|
Chemoprevention | 1 | 2017 | 91 | 0.040 |
Why?
|
Immunotherapy, Adoptive | 1 | 2018 | 170 | 0.040 |
Why?
|
Oncogene Proteins v-fos | 1 | 1996 | 3 | 0.040 |
Why?
|
HLA Antigens | 1 | 2018 | 232 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 266 | 0.040 |
Why?
|
Carcinoma, Papillary | 1 | 1998 | 158 | 0.040 |
Why?
|
Cell Shape | 1 | 2016 | 51 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2016 | 71 | 0.040 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2001 | 125 | 0.040 |
Why?
|
Metabolome | 1 | 2016 | 47 | 0.040 |
Why?
|
Endocytosis | 1 | 2017 | 177 | 0.030 |
Why?
|
Phenformin | 1 | 2015 | 5 | 0.030 |
Why?
|
Immediate-Early Proteins | 1 | 1997 | 164 | 0.030 |
Why?
|
Pentose Phosphate Pathway | 1 | 2015 | 11 | 0.030 |
Why?
|
Cell Differentiation | 3 | 2012 | 1458 | 0.030 |
Why?
|
Aspirin | 1 | 2017 | 156 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2016 | 347 | 0.030 |
Why?
|
Gadolinium DTPA | 1 | 2017 | 261 | 0.030 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2015 | 2 | 0.030 |
Why?
|
Restriction Mapping | 1 | 1995 | 157 | 0.030 |
Why?
|
RNAi Therapeutics | 1 | 2015 | 1 | 0.030 |
Why?
|
Genes, erbB-2 | 1 | 1995 | 24 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 468 | 0.030 |
Why?
|
Cyclin E | 1 | 2015 | 27 | 0.030 |
Why?
|
Male | 9 | 2011 | 40965 | 0.030 |
Why?
|
Mifepristone | 1 | 2015 | 33 | 0.030 |
Why?
|
Codon | 1 | 1995 | 124 | 0.030 |
Why?
|
Lactic Acid | 1 | 2015 | 90 | 0.030 |
Why?
|
Cell Nucleus | 2 | 2011 | 579 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2015 | 106 | 0.030 |
Why?
|
Trypsin | 1 | 1995 | 95 | 0.030 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 3 | 2001 | 113 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2015 | 59 | 0.030 |
Why?
|
Retinoblastoma Protein | 1 | 2015 | 66 | 0.030 |
Why?
|
Protein Kinases | 1 | 1996 | 209 | 0.030 |
Why?
|
Epitopes | 1 | 1995 | 255 | 0.030 |
Why?
|
Molecular Weight | 1 | 1995 | 332 | 0.030 |
Why?
|
Cisplatin | 2 | 2008 | 612 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2015 | 120 | 0.030 |
Why?
|
Random Allocation | 1 | 2015 | 332 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 115 | 0.030 |
Why?
|
Electrophoretic Mobility Shift Assay | 2 | 2005 | 72 | 0.030 |
Why?
|
Lovastatin | 1 | 2014 | 29 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2015 | 157 | 0.030 |
Why?
|
Solubility | 1 | 1995 | 177 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2015 | 164 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 160 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 192 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2014 | 251 | 0.030 |
Why?
|
Quality of Life | 1 | 2022 | 1585 | 0.030 |
Why?
|
Population Surveillance | 1 | 2015 | 219 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2014 | 91 | 0.030 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 294 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 133 | 0.030 |
Why?
|
Hungary | 1 | 1993 | 2 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 526 | 0.030 |
Why?
|
Multiphasic Screening | 1 | 1993 | 1 | 0.030 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2012 | 15 | 0.030 |
Why?
|
Liver Transplantation | 1 | 2001 | 1268 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 37 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 2012 | 44 | 0.030 |
Why?
|
Paracrine Communication | 1 | 2012 | 31 | 0.030 |
Why?
|
Vagina | 1 | 1993 | 161 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 2012 | 104 | 0.030 |
Why?
|
Umbilical Veins | 2 | 2002 | 46 | 0.030 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2012 | 62 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2014 | 679 | 0.030 |
Why?
|
Health Planning Guidelines | 1 | 2011 | 24 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 1993 | 166 | 0.030 |
Why?
|
CHO Cells | 2 | 2002 | 187 | 0.030 |
Why?
|
DNA Primers | 2 | 2004 | 543 | 0.030 |
Why?
|
Forkhead Box Protein L2 | 1 | 2011 | 3 | 0.030 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1995 | 383 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2012 | 256 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 182 | 0.020 |
Why?
|
Cricetinae | 2 | 2002 | 560 | 0.020 |
Why?
|
Cytoplasm | 2 | 2002 | 281 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2011 | 307 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 94 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 24 | 0.020 |
Why?
|
Fas Ligand Protein | 1 | 2010 | 49 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2005 | 2262 | 0.020 |
Why?
|
RNA Interference | 1 | 2011 | 369 | 0.020 |
Why?
|
Cell Lineage | 1 | 2011 | 273 | 0.020 |
Why?
|
Surface Properties | 1 | 2009 | 130 | 0.020 |
Why?
|
Snail Family Transcription Factors | 1 | 2009 | 26 | 0.020 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 28 | 0.020 |
Why?
|
Hepatocytes | 1 | 2010 | 127 | 0.020 |
Why?
|
Extracellular Matrix Proteins | 1 | 2009 | 123 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2007 | 1673 | 0.020 |
Why?
|
Formaldehyde | 1 | 2009 | 52 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 2008 | 50 | 0.020 |
Why?
|
Enzyme Activation | 2 | 2001 | 692 | 0.020 |
Why?
|
Incidence | 1 | 1993 | 1577 | 0.020 |
Why?
|
Zinc Finger E-box Binding Homeobox 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
Zinc Finger E-box-Binding Homeobox 1 | 1 | 2008 | 4 | 0.020 |
Why?
|
Stem Cells | 1 | 2011 | 351 | 0.020 |
Why?
|
Aging | 1 | 1993 | 691 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 1995 | 1169 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2008 | 151 | 0.020 |
Why?
|
Protein Transport | 1 | 2009 | 411 | 0.020 |
Why?
|
Suppression, Genetic | 1 | 2007 | 30 | 0.020 |
Why?
|
3T3 Cells | 2 | 1999 | 94 | 0.020 |
Why?
|
Prospective Studies | 1 | 2016 | 4213 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 429 | 0.020 |
Why?
|
Genes, Dominant | 1 | 2007 | 117 | 0.020 |
Why?
|
Chick Embryo | 1 | 2007 | 229 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 28 | 0.020 |
Why?
|
Femur Head | 1 | 2006 | 8 | 0.020 |
Why?
|
Lumbosacral Region | 1 | 2006 | 25 | 0.020 |
Why?
|
Reference Values | 2 | 2001 | 674 | 0.020 |
Why?
|
Ilium | 1 | 2006 | 18 | 0.020 |
Why?
|
Glioma | 1 | 2009 | 285 | 0.020 |
Why?
|
Leukopenia | 1 | 2006 | 65 | 0.020 |
Why?
|
Sacrum | 1 | 2006 | 40 | 0.020 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 94 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2007 | 254 | 0.020 |
Why?
|
Neutropenia | 1 | 2006 | 215 | 0.020 |
Why?
|
Neoplasms, Bone Tissue | 1 | 2005 | 2 | 0.020 |
Why?
|
Calcitonin | 1 | 2005 | 38 | 0.020 |
Why?
|
Anemia | 1 | 2006 | 128 | 0.020 |
Why?
|
T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2004 | 7 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 468 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2006 | 183 | 0.020 |
Why?
|
Mediastinum | 1 | 2005 | 46 | 0.020 |
Why?
|
Cervix Uteri | 1 | 2005 | 65 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2009 | 1805 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2004 | 105 | 0.020 |
Why?
|
Rats | 2 | 2001 | 3990 | 0.020 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2004 | 73 | 0.020 |
Why?
|
Angiography | 1 | 2005 | 208 | 0.020 |
Why?
|
Child, Preschool | 1 | 2011 | 3612 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2006 | 912 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2004 | 268 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 425 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 916 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2006 | 1686 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2002 | 144 | 0.010 |
Why?
|
Vesicular Biogenic Amine Transport Proteins | 1 | 2001 | 2 | 0.010 |
Why?
|
Enterochromaffin Cells | 1 | 2001 | 2 | 0.010 |
Why?
|
Vesicular Monoamine Transport Proteins | 1 | 2001 | 3 | 0.010 |
Why?
|
Chromogranin A | 1 | 2001 | 8 | 0.010 |
Why?
|
Histidine Decarboxylase | 1 | 2001 | 6 | 0.010 |
Why?
|
Chromogranins | 1 | 2001 | 11 | 0.010 |
Why?
|
Green Fluorescent Proteins | 1 | 2002 | 305 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 2001 | 63 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2005 | 2601 | 0.010 |
Why?
|
PC12 Cells | 1 | 2001 | 115 | 0.010 |
Why?
|
Platelet Activation | 1 | 2001 | 13 | 0.010 |
Why?
|
Integrin beta3 | 1 | 2001 | 30 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 2001 | 186 | 0.010 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2001 | 38 | 0.010 |
Why?
|
HELLP Syndrome | 1 | 2000 | 8 | 0.010 |
Why?
|
Guanosine Diphosphate | 1 | 2000 | 19 | 0.010 |
Why?
|
Guanosine Triphosphate | 1 | 2000 | 38 | 0.010 |
Why?
|
Imidazoles | 1 | 2001 | 162 | 0.010 |
Why?
|
Breast Diseases | 1 | 2000 | 97 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 2001 | 265 | 0.010 |
Why?
|
Monocytes | 1 | 2001 | 214 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2001 | 736 | 0.010 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 1998 | 17 | 0.010 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 1998 | 17 | 0.010 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 1998 | 24 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2001 | 339 | 0.010 |
Why?
|
Chemotaxis | 1 | 1998 | 72 | 0.010 |
Why?
|
Thyroglobulin | 1 | 1998 | 59 | 0.010 |
Why?
|
Drug Combinations | 1 | 1998 | 224 | 0.010 |
Why?
|
Proteoglycans | 1 | 1998 | 121 | 0.010 |
Why?
|
DNA Footprinting | 1 | 1997 | 18 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1998 | 265 | 0.010 |
Why?
|
Collagen | 1 | 1998 | 269 | 0.010 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1996 | 126 | 0.010 |
Why?
|
Recurrence | 1 | 1999 | 1139 | 0.010 |
Why?
|
Keratin-10 | 1 | 1993 | 1 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1998 | 469 | 0.010 |
Why?
|
Immunocompetence | 1 | 1993 | 27 | 0.010 |
Why?
|
Blood Chemical Analysis | 1 | 1993 | 42 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2000 | 2357 | 0.010 |
Why?
|
Blood Pressure | 1 | 1993 | 1143 | 0.000 |
Why?
|